<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01879917</url>
  </required_header>
  <id_info>
    <org_study_id>2012-005317-39</org_study_id>
    <secondary_id>2012-005317-39</secondary_id>
    <secondary_id>U1111-1137-3221</secondary_id>
    <nct_id>NCT01879917</nct_id>
  </id_info>
  <brief_title>Liraglutide in Newly Onset Type 1 Diabetes.</brief_title>
  <acronym>NewLira</acronym>
  <official_title>A Randomised, Double-blind, Placebo-controlled, Parallel Group, Multi-centre Trial of Liraglutide Treatment in Subjects With Newly Diagnosed Type 1 Diabetes.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hvidovre University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Steno Diabetes Center Copenhagen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hillerod Hospital, Denmark</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Bispebjerg Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Odense University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Aarhus University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Aalborg University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital of South West Denmark</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hvidovre University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the effect and safety of liraglutide 1.8 mg once
      daily compared to placebo for 52 weeks on change in beta-cell function in patients with newly
      diagnosed type 1 diabetes as an adjunctive therapy to insulin treatment.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">October 2013</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Actual">November 2018</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Beta-cell function</measure>
    <time_frame>52 weeks</time_frame>
    <description>To investigate the effect and safety of liraglutide 1.8 mg once daily compared to placebo for 52 weeks on change in beta-cell function in patients with newly diagnosed type 1 diabetes as an adjunctive therapy to insulin treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Postprandial glucagon</measure>
    <time_frame>52 weeks</time_frame>
    <description>To investigate the effect of liraglutide as compared to placebo for 52 weeks as an adjunctive therapy to insulin treatment on change in Postprandial glucagon levels following sustacal meal test.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>HbA1c</measure>
    <time_frame>52 weeks</time_frame>
    <description>To investigate the effect of liraglutide as compared to placebo for 52 weeks as an adjunctive therapy to insulin treatment on change in: HbA1c.</description>
  </other_outcome>
  <other_outcome>
    <measure>Insulin dose</measure>
    <time_frame>52 weeks</time_frame>
    <description>To investigate the effect of liraglutide as compared to placebo for 52 weeks as an adjunctive therapy to insulin treatment on change ininsulin dose.</description>
  </other_outcome>
  <other_outcome>
    <measure>Weight</measure>
    <time_frame>52 weeks</time_frame>
    <description>To investigate the effect of liraglutide as compared to placebo for 52 weeks as an adjunctive therapy to insulin treatment on change in weight.</description>
  </other_outcome>
  <other_outcome>
    <measure>Remission period</measure>
    <time_frame>52 weeks</time_frame>
    <description>To investigate the effect of liraglutide as compared to placebo for 52 weeks as an adjunctive therapy to insulin treatment on change in length of insulin remission period.</description>
  </other_outcome>
  <other_outcome>
    <measure>Hypoglycemia</measure>
    <time_frame>52 weeks</time_frame>
    <description>To investigate the effect of liraglutide as compared to placebo for 52 weeks as an adjunctive therapy to insulin treatment on change in frequency of hypoglycaemic events.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">65</enrollment>
  <condition>Diabetes Mellitus, Type 1</condition>
  <arm_group>
    <arm_group_label>Liraglutide</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1.8 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Liraglutide</intervention_name>
    <arm_group_label>Liraglutide</arm_group_label>
    <other_name>Victoza</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Saline</description>
    <arm_group_label>Saline</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Type 1 diabetes according to WHO criteria diagnosed â‰¤ 6 weeks before visit 0

          -  Age 18 - 40 years - both inclusive

          -  Postprandial C-peptide &gt; 0.2 nmol/l following sustacal meal test

          -  Able to understand the written patient information and to give informed consent

        Exclusion Criteria:

          -  Type 2 diabetes

          -  Body mass index &lt;20 kg/m2

          -  Pregnancy or unwillingness to use safe contraceptives

          -  Compromised kidney function (eGFR &lt; 60 ml/min/1,73m2), dialysis or kidney
             transplantation at visit 0

          -  Liver disease with elevated plasma alanine aminotransferase (ALT) &gt; three times the
             upper limit of normal at visit 0
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sten Madsbad, Professor</last_name>
    <role>Study Director</role>
    <affiliation>Hvidovre University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dep. of Endocrinology, Hvidovre University Hospital</name>
      <address>
        <city>Hvidovre</city>
        <state>Capital</state>
        <zip>2650</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>December 2018</verification_date>
  <study_first_submitted>June 14, 2013</study_first_submitted>
  <study_first_submitted_qc>June 17, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 18, 2013</study_first_posted>
  <last_update_submitted>December 10, 2018</last_update_submitted>
  <last_update_submitted_qc>December 10, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">December 12, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hvidovre University Hospital</investigator_affiliation>
    <investigator_full_name>Thomas Dejgaard</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>c-peptide</keyword>
  <keyword>insulin</keyword>
  <keyword>hypoglycemia</keyword>
  <keyword>Newly onset</keyword>
  <keyword>Diabetes</keyword>
  <keyword>Type 1</keyword>
  <keyword>Beta cell</keyword>
  <keyword>Autoimmune</keyword>
  <keyword>Glucagon</keyword>
  <keyword>Meal test</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liraglutide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

